Last Updated: November 16, 2026

Investigational Drug Information for Otamixaban

« Back to Dashboard


What is the drug development status for Otamixaban?

Otamixaban is an investigational drug.

There have been 5 clinical trials for Otamixaban. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2010.

The most common disease conditions in clinical trials are Acute Coronary Syndrome, Infarction, and Angina, Unstable. The leading clinical trial sponsors are Sanofi and [disabled in preview].

Recent Clinical Trials for Otamixaban
TitleSponsorPhase
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic ImpairmentSanofiPhase 1
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive StrategySanofiPhase 3
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal ImpairmentSanofiPhase 1

See all Otamixaban clinical trials

Clinical Trial Summary for Otamixaban

Top disease conditions for Otamixaban
Top clinical trial sponsors for Otamixaban

See all Otamixaban clinical trials

Otamixaban Development Update, Patent Status, and Market Projection

Last updated: September 8, 2026

Otamixaban is a discontinued investigational intravenous direct factor Xa inhibitor developed by Sanofi for acute coronary syndromes. Its Phase III SEPIA-ACS2 trial failed to reduce ischemic events compared with unfractionated heparin plus eptifibatide and caused substantially more bleeding. Sanofi discontinued development in 2011. Otamixaban has no FDA approval, no Orange Book listing, no marketed product, and no credible near-term commercial market projection. [1-4]

What is the current development status of otamixaban?

Otamixaban development is inactive. Sanofi stopped the program after the Phase III SEPIA-ACS2 TIMI 52 trial failed its primary efficacy endpoint. The candidate has not advanced into a new indication, formulation, or regulatory pathway since that decision. [1,2]

Development element Status
Active ingredient Otamixaban, an intravenous direct factor Xa inhibitor
Developer Sanofi
Primary indication Non-ST-elevation acute coronary syndromes
Administration Intravenous bolus and infusion
Development stage reached Phase III
Regulatory approval None
FDA approval date None
Commercial launch None
Current clinical development Discontinued
Current revenue Zero product revenue

Otamixaban was designed to provide rapid, direct inhibition of factor Xa during acute coronary intervention and related hospital treatment. The development strategy focused on replacing or improving upon unfractionated heparin and other parenteral anticoagulants used with antiplatelet therapy.

Why did Sanofi discontinue otamixaban?

The Phase III SEPIA-ACS2 trial did not show a meaningful efficacy advantage and showed a clinically unfavorable bleeding profile. The trial enrolled more than 15,000 patients with non-ST-elevation acute coronary syndromes.

Outcome in SEPIA-ACS2 Otamixaban Control therapy Result
Primary ischemic endpoint 5.5% 5.7% No significant benefit
TIMI major or minor bleeding Approximately 3.1% Approximately 1.5% About twofold higher with otamixaban
Trial conclusion No efficacy improvement Standard comparator Development did not support continuation

The trial compared otamixaban with unfractionated heparin plus eptifibatide. Otamixaban failed to improve the composite ischemic endpoint of death, myocardial infarction, recurrent ischemia requiring urgent revascularization, or stent thrombosis. Bleeding was materially higher with otamixaban. [2]

Sanofi announced termination of the program in July 2011 after reviewing the SEPIA-ACS2 results. The company did not pursue a reformulated dose, a narrower patient population, or a secondary indication. [1]

What were the key otamixaban clinical trials?

SEPIA-ACS1 TIMI 42

SEPIA-ACS1 was a Phase II dose-finding study in patients with non-ST-elevation acute coronary syndromes. It evaluated several otamixaban dosing regimens against unfractionated heparin plus eptifibatide.

The study indicated that otamixaban could reduce ischemic events at selected doses, but higher exposure increased bleeding. The dose-response relationship created a narrow therapeutic margin for the subsequent Phase III program.

SEPIA-ACS2 TIMI 52

SEPIA-ACS2 was the pivotal Phase III study. It evaluated otamixaban in a large acute coronary syndrome population undergoing an invasive or conservative treatment strategy.

The trial did not confirm the Phase II efficacy signal. Bleeding risk increased without a corresponding reduction in ischemic events. The clinical profile was unfavorable against established parenteral anticoagulants, and Sanofi terminated the program.

Trial Phase Population Comparator Outcome
SEPIA-ACS1 TIMI 42 II Non-ST-elevation ACS UFH plus eptifibatide Dose-response signal, bleeding concerns
SEPIA-ACS2 TIMI 52 III More than 15,000 NSTE-ACS patients UFH plus eptifibatide No efficacy benefit, higher bleeding
Post-Phase III program Not applicable No new clinical population Not applicable Discontinued

What is the FDA regulatory status of otamixaban?

Otamixaban is not FDA approved. There is no approved otamixaban product in Drugs@FDA, no approved labeling, and no recognized U.S. marketing authorization. [3]

The candidate also has no established FDA exclusivity period. It did not receive new chemical entity exclusivity, orphan-drug exclusivity, pediatric exclusivity, or approval-related market exclusivity because no application produced an approved product.

What is the Orange Book status of otamixaban?

Otamixaban has no Orange Book listing. The FDA Orange Book lists approved drug products and relevant patents or exclusivity associated with approved applications. Because otamixaban was never approved, there is no listed reference product, no Orange Book patent certification pathway, and no standard Paragraph IV challenge against an otamixaban product. [4]

What patents protect otamixaban?

Otamixaban was developed as a proprietary Sanofi compound, but there is no active FDA-listed patent estate associated with a marketed otamixaban product.

The key commercial distinction is that a patent may have existed at the compound, formulation, or manufacturing level without creating an active Orange Book barrier. Since otamixaban never received FDA approval, there is no approved-product patent listing to block a generic filing.

Patent category Commercial status
Compound patent Historical development protection may have existed
Formulation patent No approved U.S. product listing
Method-of-use patent No FDA-approved use tied to otamixaban
Manufacturing patent Could affect production, but no marketed product is known
Orange Book patent None
Paragraph IV litigation None identified against an approved otamixaban reference product

The absence of an Orange Book listing does not mean every historical patent family has expired or been abandoned. It means those patents do not create a current FDA-listed barrier comparable to the patent estate for an approved branded drug.

When does otamixaban lose exclusivity?

Otamixaban has no current FDA market exclusivity because it never obtained approval. The practical exclusivity event was the failure and discontinuation of clinical development, not a defined patent-expiration date.

No generic company has a commercial incentive to file an abbreviated new drug application for otamixaban without an approved reference product and an established clinical market. A new sponsor would likely need to pursue a full development and approval strategy rather than rely on a conventional ANDA pathway.

Are there Paragraph IV challenges or otamixaban patent lawsuits?

No commercially significant Paragraph IV litigation is associated with otamixaban. The reason is structural: there is no approved otamixaban reference listed in the Orange Book.

No major U.S. patent litigation, settlement agreement, or generic launch dispute has shaped the product's commercial status. Sanofi's decision ended the program before a branded launch created the usual patent, licensing, or generic-entry disputes.

Are there formulation patents or manufacturing barriers?

Otamixaban was administered intravenously, which created technical requirements involving sterility, stability, dosing precision, and hospital-use preparation. Those requirements could have supported formulation or manufacturing patent claims during development.

They do not create a significant current market barrier because:

  1. There is no approved commercial formulation.
  2. No active branded supply chain exists.
  3. No established hospital purchasing market exists.
  4. A new sponsor would need to reproduce the clinical benefit and establish an acceptable bleeding profile.
  5. The principal barrier is clinical validation, not formulation access.

A follow-on developer could theoretically investigate a lower-dose regimen, a targeted procedural indication, or a redesigned delivery system. The Phase III failure makes that strategy commercially difficult because the core risk was an unfavorable benefit-risk balance rather than a simple delivery limitation.

How does otamixaban compare with competing anticoagulants?

Otamixaban competed in a hospital anticoagulation market dominated by established therapies and newer agents with stronger clinical positioning.

Drug or class Primary role in the relevant market Commercial position versus otamixaban
Unfractionated heparin Procedural and acute hospital anticoagulation Established standard and comparator
Bivalirudin Direct thrombin inhibitor for procedural anticoagulation Approved and commercially established
Fondaparinux Factor Xa pathway anticoagulation in ACS Approved for selected ACS use
Eptifibatide GP IIb/IIIa antiplatelet therapy Used with anticoagulants in the pivotal trial
Rivaroxaban Oral factor Xa inhibitor Approved for selected cardiovascular indications, not a direct otamixaban substitute in the Phase III setting
Apixaban Oral factor Xa inhibitor Stronger commercial franchise in chronic indications
Otamixaban Intravenous investigational factor Xa inhibitor Discontinued and unapproved

Otamixaban's mechanism was differentiated from heparin, but mechanistic differentiation did not translate into superior clinical outcomes. The program also faced competition from agents with established dosing protocols, hospital familiarity, and regulatory approval.

What is the market projection for otamixaban?

The base-case market projection is zero. Otamixaban has no approved indication, no active commercial supply, no sales, and no identifiable near-term launch pathway.

Projection scenario Probability assessment Commercial implication
No further development Base case No revenue and no market share
Restart by Sanofi Highly remote Would require a new clinical and regulatory program
Licensing to another company Remote Limited value after Phase III failure
Reformulation or lower-dose development Speculative Requires new proof of efficacy and bleeding control
Generic or biosimilar entry Not applicable Otamixaban is a small molecule, not a biologic, and has no approved reference product

A relaunch would require more than manufacturing access. A sponsor would likely need to:

  • Define a patient population with a clearer benefit-risk profile.
  • Select a dose that avoids excess bleeding.
  • Conduct a new pivotal trial.
  • Establish compatibility with contemporary antiplatelet and interventional treatment.
  • Obtain FDA approval for a new drug application.
  • Build hospital adoption against low-cost heparin and established alternatives.

The commercial opportunity is therefore limited by development risk, not by patent expiry. A successful relaunch would also face generic pricing pressure from heparin and intense competition from approved anticoagulants.

Which companies are challenging otamixaban?

No major company is publicly pursuing a commercial challenge to otamixaban. The candidate is not an active branded product, and there is no identified generic, biosimilar, or competing licensee preparing a launch.

Biosimilar competition is irrelevant because otamixaban is a chemically synthesized small molecule rather than a biologic. A future copy product would be evaluated under a small-molecule drug pathway, but the absence of an approved reference product makes a standard generic strategy impractical.

What licensing deals involve otamixaban?

No material current licensing or commercialization agreement has established a market for otamixaban. Sanofi was the principal developer and retained control of the program through its discontinuation.

There is no publicly established post-discontinuation transaction that has revived otamixaban development or transferred the asset into an active clinical portfolio.

What patent strength does otamixaban have today?

Otamixaban has low practical patent strength as a commercial asset. Any historical compound or process patents must be assessed separately from FDA-listed protection, but they do not support an active branded market.

Patent-strength factor Assessment
Approved product None
Orange Book protection None
Active clinical program None
Generic challenge risk Low relevance because no product is marketed
Manufacturing exclusivity No demonstrated commercial effect
Litigation leverage Minimal
Asset value Primarily contingent on successful redevelopment

Key Takeaways

  • Otamixaban is a discontinued Sanofi intravenous factor Xa inhibitor.
  • Sanofi ended development after the Phase III SEPIA-ACS2 trial showed no ischemic benefit and approximately twice the bleeding rate of control therapy.
  • The FDA has never approved otamixaban.
  • Otamixaban has no Orange Book listing, FDA exclusivity, marketed formulation, or approved reference product.
  • No meaningful Paragraph IV litigation, generic challenge, biosimilar risk, or commercial settlement is associated with the asset.
  • The current market projection is zero revenue.
  • Any future value would depend on a new development program that solves the failed benefit-risk balance.

FAQs

Could otamixaban be revived for a different indication?

Yes, in principle, but revival would require new clinical evidence and likely a new pivotal trial. The prior Phase III failure would remain a central regulatory and commercial liability.

Is otamixaban a direct oral anticoagulant?

No. Otamixaban was developed as an intravenous direct factor Xa inhibitor for acute hospital use. It was not positioned as an oral chronic anticoagulant like rivaroxaban or apixaban.

Is otamixaban interchangeable with rivaroxaban?

No. Both inhibit factor Xa, but they have different routes of administration, clinical settings, dosing strategies, and regulatory histories.

Does otamixaban have biosimilar competition?

No. Biosimilar rules apply to biologic products. Otamixaban is a small-molecule drug candidate and was never approved as a biologic or reference product.

What caused the commercial failure of otamixaban?

The program failed because the pivotal trial did not improve ischemic outcomes and increased bleeding. The resulting benefit-risk profile did not justify regulatory approval or commercial investment.

References

  1. Sanofi. (2011, July 21). Sanofi discontinues development of otamixaban in acute coronary syndromes. Sanofi press release.

  2. Steg, P. G., Mehta, S. R., Pollack, C. V., Jr., Huber, K.,Ido, A., Clark, A. M., et al. (2013). Otamixaban for acute coronary syndromes. New England Journal of Medicine, 368(22), 2084-2094. https://doi.org/10.1056/NEJMoa1301541

  3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

  4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.